Page last updated: 2024-08-25

ceric oxide and Dyslipidemias

ceric oxide has been researched along with Dyslipidemias in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	1 (100.00)	2.80

Authors

Authors	Studies
Abd El-Monem, AM; Ali, RH; El Agaty, SM; Galal Hamam, G; Lasheen, NN; Lebda, FM	1

Other Studies

1 other study(ies) available for ceric oxide and Dyslipidemias

Article	Year
Cerium oxide nanoparticles modulate liver X receptor and short heterodimer partner, and attenuate liver steatosis and steatohepatitis in a rat model of postmenopausal obesity. General physiology and biophysics, 2022, Volume: 41, Issue:5 Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cerium; Dyslipidemias; Fatty Acids, Nonesterified; Female; Fibrosis; Fructose; Humans; Liver; Liver X Receptors; Malondialdehyde; Nanoparticles; Non-alcoholic Fatty Liver Disease; Obesity; Ovariectomy; Postmenopause; Rats; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha	2022

Article

Year

Cerium oxide nanoparticles modulate liver X receptor and short heterodimer partner, and attenuate liver steatosis and steatohepatitis in a rat model of postmenopausal obesity.

General physiology and biophysics, 2022, Volume: 41, Issue:5

Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cerium; Dyslipidemias; Fatty Acids, Nonesterified; Female; Fibrosis; Fructose; Humans; Liver; Liver X Receptors; Malondialdehyde; Nanoparticles; Non-alcoholic Fatty Liver Disease; Obesity; Ovariectomy; Postmenopause; Rats; Transforming Growth Factor beta1; Tumor Necrosis Factor-alpha

2022